These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 15878569

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease.
    Anand P, Singh B, Singh N.
    Bioorg Med Chem; 2012 Feb 01; 20(3):1175-80. PubMed ID: 22257528
    [Abstract] [Full Text] [Related]

  • 7. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L, Giraldi C, Saccardo M, Cammarata S, Bottini G, Fasanaro AM, Trequattrini A, Upgrade Study Group.
    Curr Med Res Opin; 2005 Nov 01; 21(11):1809-18. PubMed ID: 16307702
    [Abstract] [Full Text] [Related]

  • 8. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
    Castro A, Martinez A.
    Mini Rev Med Chem; 2001 Sep 01; 1(3):267-72. PubMed ID: 12369973
    [Abstract] [Full Text] [Related]

  • 9. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
    Kwon YE, Park JY, No KT, Shin JH, Lee SK, Eun JS, Yang JH, Shin TY, Kim DK, Chae BS, Leem JY, Kim KH.
    Bioorg Med Chem; 2007 Oct 15; 15(20):6596-607. PubMed ID: 17681794
    [Abstract] [Full Text] [Related]

  • 10. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.
    Samadi A, de los Ríos C, Bolea I, Chioua M, Iriepa I, Moraleda I, Bartolini M, Andrisano V, Gálvez E, Valderas C, Unzeta M, Marco-Contelles J.
    Eur J Med Chem; 2012 Jun 15; 52():251-62. PubMed ID: 22503231
    [Abstract] [Full Text] [Related]

  • 11. Binding of the neurotoxin fasciculin 2 to the acetylcholinesterase peripheral site drastically reduces the association and dissociation rate constants for N-methylacridinium binding to the active site.
    Rosenberry TL, Rabl CR, Neumann E.
    Biochemistry; 1996 Jan 23; 35(3):685-90. PubMed ID: 8547248
    [Abstract] [Full Text] [Related]

  • 12. Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates.
    Camps P, Formosa X, Galdeano C, Gómez T, Muñoz-Torrero D, Ramírez L, Viayna E, Gómez E, Isambert N, Lavilla R, Badia A, Clos MV, Bartolini M, Mancini F, Andrisano V, Bidon-Chanal A, Huertas O, Dafni T, Luque FJ.
    Chem Biol Interact; 2010 Sep 06; 187(1-3):411-5. PubMed ID: 20167211
    [Abstract] [Full Text] [Related]

  • 13. Acetylcholinesterase complexed with bivalent ligands related to huperzine a: experimental evidence for species-dependent protein-ligand complementarity.
    Wong DM, Greenblatt HM, Dvir H, Carlier PR, Han YF, Pang YP, Silman I, Sussman JL.
    J Am Chem Soc; 2003 Jan 15; 125(2):363-73. PubMed ID: 12517147
    [Abstract] [Full Text] [Related]

  • 14. Substrate binding to the peripheral site of acetylcholinesterase initiates enzymatic catalysis. Substrate inhibition arises as a secondary effect.
    Szegletes T, Mallender WD, Thomas PJ, Rosenberry TL.
    Biochemistry; 1999 Jan 05; 38(1):122-33. PubMed ID: 9890890
    [Abstract] [Full Text] [Related]

  • 15. Discovery of acetylcholinesterase peripheral anionic site ligands through computational refinement of a directed library.
    Dickerson TJ, Beuscher AE, Rogers CJ, Hixon MS, Yamamoto N, Xu Y, Olson AJ, Janda KD.
    Biochemistry; 2005 Nov 15; 44(45):14845-53. PubMed ID: 16274232
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues.
    Bolognesi ML, Bartolini M, Cavalli A, Andrisano V, Rosini M, Minarini A, Melchiorre C.
    J Med Chem; 2004 Nov 18; 47(24):5945-52. PubMed ID: 15537349
    [Abstract] [Full Text] [Related]

  • 17. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.
    Musiał A, Bajda M, Malawska B.
    Curr Med Chem; 2007 Nov 18; 14(25):2654-79. PubMed ID: 17979717
    [Abstract] [Full Text] [Related]

  • 18. Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
    Arce MP, Rodríguez-Franco MI, González-Muñoz GC, Pérez C, López B, Villarroya M, López MG, García AG, Conde S.
    J Med Chem; 2009 Nov 26; 52(22):7249-57. PubMed ID: 19856923
    [Abstract] [Full Text] [Related]

  • 19. Discovery of dual binding site acetylcholinesterase inhibitors identified by pharmacophore modeling and sequential virtual screening techniques.
    Gupta S, Fallarero A, Järvinen P, Karlsson D, Johnson MS, Vuorela PM, Mohan CG.
    Bioorg Med Chem Lett; 2011 Feb 15; 21(4):1105-12. PubMed ID: 21273074
    [Abstract] [Full Text] [Related]

  • 20. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease.
    Camps P, Cusack B, Mallender WD, El Achab RE, Morral J, Muñoz-Torrero D, Rosenberry TL.
    Mol Pharmacol; 2000 Feb 15; 57(2):409-17. PubMed ID: 10648652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.